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Abstract 13 
Virus-encoded miRNAs are emerging as key regulators of persistent infection and host-cell 14 
immune evasion. Merkel cell polyomavirus (MCPyV), the predominant aetiological agent of 15 
Merkel cell carcinoma (MCC), encodes a single miRNA, MCV-miR-M1, which targets the 16 
oncogenic MCPyV large T antigen (LT). MCV-miR-M1 has previously been shown to play 17 
an important role in establishment of long-term infection, however, the underlying 18 
mechanism is not fully understood. A key unanswered question is whether, in addition to 19 
auto-regulating LT, MCV-miR-M1 also targets cellular transcripts to orchestrate an 20 
environment conducive for persistent infection. To address this, we adopted an RNA-Seq-21 
based approach to identify cellular targets of MCV-miR-M1. Intriguingly, bioinformatics 22 
analysis of transcripts that are differentially expressed in cells expressing MCV-miR-M1 23 
revealed several genes implicated in immune evasion. Subsequent target validation led to the 24 
identification of the innate immunity protein, SP100, as a direct target of MCV-miR-M1. 25 
Moreover, MCV-miR-M1-mediated modulation of SP100 was associated with a significant 26 
decrease in CXCL8 secretion, resulting in the attenuation of neutrophil chemotaxis towards 27 
Merkel cells harbouring synthetic MCPyV. Based on these observations we propose that 28 
MCV-miR-M1 targets key immune response regulators to help facilitate persistent infection, 29 
which is a pre-requisite for cellular transformation in MCC.    30 
Introduction  31 
Merkel cell polyomavirus (MCPyV) is the aetiological agent in MCPyV-positive Merkel cell 32 
carcinoma (MCC), a rare but aggressive skin cancer that typically occurs in 33 
immunocompromised individuals (recently reviewed by (Grundhoff and Fischer, 2015, Liu et 34 
al., 2016a)). Following the discovery of MCPyV in 2008 (Feng et al., 2008), research has 35 
principally focused on the role of the large and small tumour antigens (LT and sT, 36 
respectively). To this end, the last decade has seen a dearth of studies demonstrating how LT 37 
and sT usurp or perturb an array of host cell mechanisms to promote virus replication, create 38 
a conducive environment for persistent infection and promote transformation and MCC 39 
metastasis (Abdul-Sada et al., 2017, Arora et al., 2012, Cheng et al., 2013, Griffiths et al., 40 
2013a, Houben et al., 2012, Knight et al., 2015, Kwun et al., 2013, Kwun et al., 2017, Liu et 41 
al., 2011, Shuda et al., 2008, Verhaegen et al., 2017). MCPyV-mediated attenuation of the 42 
innate immune response following infection and during virus replication is thought to enable 43 
a quasi-latent MCPyV infection in Merkel cells, an event presumed to be a pre-requisite for 44 
the development of MCC. Several elegant studies have demonstrated that LT and sT function 45 
to diminish the immunological footprint of MCPyV by targeting host innate immune 46 
components, including TLR9 (Shahzad et al., 2013) and the NF-κB essential modulator, 47 
NEMO (Abdul-Sada et al., 2017, Griffiths et al., 2013a). This approach is representative of 48 
convergent and divergent mechanisms that have evolved in most, if not all, DNA viruses. For 49 
example, similar immune evasion strategies have been reported in the pathogenic human 50 
polyomaviruses, JC and BK (Bauman et al., 2011) and in human papillomavirus (Tummers et 51 
al., 2015). The master exponents of host-immune evasion are herpesviruses, which utilise a 52 
plethora of approaches to manipulate the host cell immune response, including; 53 
destabilisation of host cell mRNA (Rowe et al., 2007), proteasome-mediated degradation of 54 
host antiviral proteins (Wiertz et al., 1996) and derailment of host cell innate immunity (Sun 55 
et al., 2015). As is the case for MCPyV, early studies on herpesvirus-mediated host immune 56 
evasion centred on virus-encoded proteins, however, pioneering work in HCMV (Stern-57 
Ginossar et al., 2007) followed by studies in EBV (Xia et al., 2008) and KSHV (Nachmani et 58 
al., 2009), rapidly established a pivotal role for virus-encoded miRNAs in the derailment of 59 
the host cell immune response. 60 
From the perspective of a virus, non-coding RNAs (ncRNA) are extremely attractive 61 
regulatory molecules; they take up very little genomic real estate, a single ncRNA can impact 62 
hundreds of cellular targets and, crucially, they are non-immunogenic. In recent years, there 63 
has been a significant shift in our appreciation of the prevalence and importance of virus 64 
miRNAs in the replication and associated pathologies of DNA viruses. Human herpesviruses 65 
from all three subfamilies (-, - and -) have been reported to dampen immune response via 66 
the expression of numerous miRNAs that target different facets of the host-immune response 67 
network (Giffin and Damania, 2014, Zuo et al., 2017). This strategy is not limited to the large 68 
DNA viruses, the pathogenic polyomaviruses BK and JC encode identical miRNAs that 69 
target and translationally represses the NK-receptor ligand, ULBP3, an event that is required 70 
to establish a persistent infection in host cells (Bauman et al., 2011). MCPyV encodes a 71 
single primary miRNA, that is processed to produce MCV-miR-M1-5p and MCV-miR-M1-72 
3p (Lee et al., 2011, Seo et al., 2009). MCV-miR-M1 is expressed from the antisense strand 73 
of the LT ORF and thus exhibits perfect sequence complementarity to a region in exon two of 74 
the MCPyV LT mRNA transcript. Indeed, MCV-miR-M1 has been shown to attenuate the 75 
expression of LT via dual-luciferase reporter assay (Seo et al., 2009), a function it shares with 76 
orthologous miRNAs encoded by the other human polyomaviruses (Imperiale, 2014).  77 
 78 
MCV-miR-M1-mediated attenuation of LT expression is believed to dampen the host cell 79 
immune response during polyomavirus replication, a hypothesis that is supported by studies 80 
on SV40 polyomavirus, where susceptibility to cytotoxic T-cells was significantly increased 81 
in SV40 miRNA-mutant infected cells compared with cells infected with wild type SV40 82 
(Sullivan et al., 2005).  Strikingly, a similar observation was recently reported for MCPyV, 83 
where a miRNA-deficient synthetic MCPyV loses its ability to establish long term infection 84 
(Theiss et al., 2015). While these observations suggest an essential role for polyomavirus 85 
miRNAs in host immune evasion and persistent infection, it is yet to be determined if 86 
polyomavirus miRNAs function solely by downregulating LT. An intriguing possibility is 87 
that, MCV-miR-M1, like the BK/JC miRNA, also manipulates the expression of cellular 88 
immune system transcripts to facilitate an environment in the host-cell that is conducive for 89 
long-term infection. 90 
To date, the only proposed cellular targets for MCV-miR-M1 were derived via in silico 91 
analysis of the MCV-miR-M1-5p seed sequence (Lee et al., 2011). However, a meticulous 92 
miRNA-seq-based study of MCV-miR-M1 expression has since called into doubt the validity 93 
of these targets, due to a discrepancy in the seed sequence used in their identification (Theiss 94 
et al., 2015).  Herein, we describe an unbiased RNA-seq-based analysis of MCV-miR-M1-5p 95 
and MCV-miR-M1-3p cellular targets. These data demonstrate that MCV-miR-M1 alters the 96 
expression of numerous cellular transcripts. Specifically, direct targeting of the intrinsic 97 
antiviral protein, SP100, during MCPyV replication leads to a reduction in the secretion of 98 
CXCL8 and a significant decrease in neutrophil chemotaxis towards host-cells harbouring 99 
replicative MCPyV. Together, these data describe a mechanism for MCV-miR-M1-mediated 100 
subversion of the host cell immune response that is likely to contribute to the reported role of 101 
MCV-miR-M1 in establishing long-term MCPyV infection in skin. 102 
Results  103 
MCV-miR-M1 downregulates the expression of numerous cellular immune transcripts. 104 
To determine the effect of MCV-miR-M1 expression on cellular transcript levels 105 
independently of other MCPyV transcripts and proteins, we developed inducible stable cell 106 
line, transient transfection and mimic-based in vitro expression systems for MCV-miR-M1. 107 
The comparative expression of MCV-miR-M1 in these different systems was assessed via 108 
stem-loop qRT-PCR (Figure 1a) and their functional activity against their cognate target in 109 
LT determined using dual-luciferase assay (DLA) (Figure 1b). As can be seen in Figure 1b, 110 
MCV-miR-M1 mimics exhibited increased activity against the MCV-miR-M1 cognate 111 
recognition sequence compared with transient transfection of an MCV-miR-M1 expression 112 
construct. This observation, in combination with the opportunity to dissect 5p and 3p cellular 113 
targets (an important consideration given the fact that the MCV-miR-M1 orthologue in 114 
JC/BK polyomavirus derails host-cell innate immune response via the 3p arm (Bauman et al., 115 
2011)), prompted us to utilise MCV-miR-M1 mimics in our comparative expression studies. 116 
RNA-Seq analysis of MCV-miR-M1 mimic-transfected 293 cells identified 70 and 111 117 
cellular transcripts that showed significant differential expression in the presence of MCV-118 
miR-M1-5p and MCV-miR-M1-3p, respectively (Table S1). Strikingly, gene annotation 119 
analysis using DAVID (Dennis et al., 2003) revealed an overrepresentation of gene 120 
ontologies (GO) relating to regulation of cell communication and immune system pathways 121 
(Figure 2a). Analysis of dysregulated immune-system transcripts produced a list of putative 122 
MCV-miR-M1 targets with proposed functional roles in the evasion of host-cell immune 123 
response (Figure 2b). 124 
MCV-miR-M1 downregulates cellular immune transcripts during MCPyV replication 125 
MCV-miR-M1-5p and MCV-miR-M1-3p targets identified via RNA-seq were initially 126 
validated by transient transfection of 293 cells with the respective MCV-miR-M1 mimic, 127 
followed by analysis of target transcript levels by qRT-PCR. In each instance, qRT-PCR 128 
based analysis corroborated our RNA-seq data, demonstrating MCV-miR-M1-5p and MCV-129 
miR-M1-3p specificity for several immune system-related transcripts (Figure 3a). To confirm 130 
if cellular targets identified via RNA-seq are also targeted by MCV-miR-M1 in the context of 131 
an MCPyV infection, we utilised a previously reported MCPyV replication system based on 132 
synthetic MCPyV genomes (MCVSyn) that are identical to prototypical field strain 133 
sequences (Neumann et al., 2011). Moreover, a modified MCVSyn (MCVSyn-hpko) mutated 134 
to disrupt the MCV-miR-M1 pre-miRNA hairpin structure (Theiss et al., 2015) served as a 135 
negative control. Importantly, both synthetic MCPyV genomes have been shown to undergo 136 
virus replication in 293 cells to produce increases in genome copy number that are detectable 137 
via qRT-PCR (Theiss et al., 2015). To confirm that 293 cells transfected with MCVSyn 138 
express functional MCV-miR-M1-5p and MCV-miR-M1-3p, stem-loop qRT-PCR (Figure 139 
3b) and analysis of LT expression (Figure 3c) was carried out over a 72h period. As can be 140 
seen in Figure 3b, MCV-miR-M1-5p and MCV-miR-M1-3p expression was readily detected 141 
in cells transfected with MCVSyn, however, 293 cells transfected with MCVSyn-hpko 142 
displayed no detectable expression of MCV-miR-M1. Moreover, data in Figure 3c 143 
demonstrate that LT expression inversely correlates with expression of MCV-miR-M1, we 144 
also detected an increase in MCPyV genome copy number 72h post-transfection (Figure 145 
S2a), in agreement with previously published data characterising the MCVSyn system. We 146 
next sought to validate MCV-miR-M1-5p and MCV-miR-M1-3p mimic targets identified via 147 
RNA-seq in the context of MCPyV replication. As shown in Figure 3d, cellular transcripts 148 
identified as MCV-miR-M1 mimic targets in our RNA-seq data set and associated with 149 
immune system GO were significantly down-regulated in 293 cells harbouring replicative 150 
wild type MCVSyn but not in 293 cells transfected with MCVSyn-hpko mutant. Together 151 
these data confirm that MCV-miR-M1 expression during MCPyV replication results in the 152 
significant decrease of several cellular transcripts associated with host-cell immune response. 153 
The antiviral innate immunity regulator, SP100, is a direct target of MCV-miR-M1-5p 154 
Having established that MCV-miR-M1 expression during MCPyV replication decreased the 155 
level of several host cell immune transcripts, we were keen to determine if any of these 156 
dysregulated mRNAs were direct targets of MCV-miR-M1-5p or MCV-miR-M1-3p. To 157 
address this, we initially carried out an in silico analysis on the 3’UTR region of each MCV-158 
miR-M1 target listed in Figure 2b, using RNA-hybrid (Rehmsmeier et al., 2004). 159 
Interrogation of RNA-hybrid data revealed putative MCV-miR-M1 seed sequence 160 
recognition sites in the 3’UTR regions of CXCL8, RAET1G, SELPLG and SP100 (Figure 161 
4a). To determine if transcripts containing putative MCV-miR-M1 seed sequence-binding 162 
sites were direct targets of the MCV-miR-M1, DLA assays were performed using MCV-miR-163 
M1 mimics. As can be seen in Figure 4b, only the SP100 3’-UTR DLA construct exhibited a 164 
nominal but consistent and significant decrease in normalised luciferase signal, which was 165 
more pronounced in SP100 3’-UTR deletions (Figure S1). This decrease was observed when 166 
the SP100 3’-UTR DLA construct was co-transfected with MCV-miR-M1-5p mimic or the 167 
MCVSyn genome, however, no decrease was observed in 293 cells co-transfected with 168 
scramble mimic, MCV-miR-M1-3p mimic or the MCVSyn-hpko mutant (Figure 4c), 169 
suggesting that the observed MCV-miR-M1-dependent decrease in SP100 mRNA is due to 170 
direct targeting and translational repression of the SP100 transcript by MCV-miR-M1-5p. To 171 
confirm this, the putative MCV-miR-M1-5p recognition sequence in the SP100 3’-UTR was 172 
mutated and DLA assays repeated. Mutation of the putative MCV-miR-M1-5p seed sequence 173 
recognition site completely abolished MCV-miR-M1-5p- and MCVSyn-mediated decrease of 174 
luciferase signal, confirming that the direct targeting of the SP100 transcript by MCV-miR-175 
M1-5p is dependent on this region of the SP100 3’-UTR (Figure 4d). Finally, we sought to 176 
establish if direct targeting of SP100 mRNA transcript by MCV-miR-M1-5p impacted on 177 
SP100 protein levels. Figure 4e clearly shows that SP100 protein levels are significantly 178 
reduced in cells transfected with MCV-miR-M1-5p or MCVSyn, compared to negative 179 
controls.  Together, these data demonstrate that SP100 is a direct target of MCV-miR-M1-5p 180 
and this targeting results in diminished SP100 protein levels during MCPyV replication. 181 
MCV-miR-M1-dependent decrease in SP100 modulates secretion of CXCL8  182 
CXCL8 plays an integral role in inducing neutrophil activation and migration in the skin in 183 
response to viral infection (Colditz and Watson, 1992) and is downregulated in our RNA-seq 184 
data set and during MCPyV replication (Figure 2a; Figure 3d). However, despite the presence 185 
of a putative MCV-miR-M1-3p seed sequence match in the 3’-UTR of CXCL8, DLA data 186 
shown in Figure 4b suggest that the effect of MCV-miR-M1 on the CXCL8 transcript level is 187 
indirect. Despite the indirect nature of MCV-miR-M1-induced CXCL8 transcript changes, 188 
given the importance of CXCL8 in the antiviral response in skin we were eager to determine 189 
if this resulted in diminished secretion of CXCL8. To address this question, conditioned 190 
media was collected from TNF-α stimulated 293 cells 24h post-transfection with mimics and 191 
unstimulated 293 cells transfected with either MCVSyn or MCVSyn-hpko genomes and 192 
CXCL8 secretion analysed via ELISA. We observed significantly reduced levels of CXCL8 193 
in media collected from TNF-α-stimulated 293 cells transfected with both MCV-miR-M1-5p 194 
and MCV-miR-M1-3p mimics, compared with scramble mimic control (Figure 5a). CXCL8 195 
levels were also significantly lower in 293 cells harbouring the wild type MCVSyn, 196 
compared with cells transfected with the MCVSyn-hpko miRNA mutant (Figure 5b).  197 
The observation that MCV-miR-M1-5p mimic attenuated CXCL8 secretion is intriguing, as 198 
we did not observe any decrease in CXCL8 transcript levels in 293 cells transfected with this 199 
arm of the virus miRNA, either via RNA-seq (Table S1) or qRT-PCR (Figure 6a). A possible 200 
explanation for this is that MCV-miR-M1-5p mediated reduction in SP100 expression 201 
impacts on CXCL8 secretion. While there is evidence to support a role for PML-bodies in the 202 
regulation of cytokine gene expression (Ohgiya et al., 2012), there is no evidence to support a 203 
direct role for SP100 in regulating CXCL8 expression. To test if observed decreases in 204 
secreted CXCL8 in 293 cells transfected with MCV-miR-M1-5p were related to the 5p-205 
mediated decrease in SP100 protein expression the open reading frame of SP100 lacking the 206 
endogenous 3’-UTR was PCR cloned to generate pCDNA-SP100. Co-transfection of 293 207 
cells with pCDNA-SP100 and either MCV-miR-M1-5p or MCVSyn prevented MCV-miR-208 
M1-mediated downregulation of SP100 protein (Figure 5c) and led to the partial rescue of 209 
CXCL8 secretion, compared with MCV-miR-M1-3p or negative controls (Figures 5d and 210 
5e). Together these data demonstrate that there is an MCV-miR-M1-dependent decrease in 211 
CXCL8 secretion during MCPyV replication and that this reduction is mediated in part via 212 
direct targeting of SP100 by MCV-miR-M1-5p. 213 
Diminished migration of neutrophils towards cells harbouring MCPyV.  214 
CXCL8 is a neutrophil chemoattractant and activator (Baggiolini et al., 1989, Harada et al., 215 
1994) that modulates neutrophil migration (Huber et al., 1991) and is an important 216 
component of the innate immune response to virus infection in skin (de Oliveira et al., 2016). 217 
To establish if MCV-miR-M1-dependent downregulation of CXCL8 during MCPyV 218 
replication is significant in terms of attenuating neutrophil chemotaxis, trans-well migration 219 
assays were performed. Neutrophil migration was significantly impaired towards conditioned 220 
media from both MCV-miR-M1-5p and -3p mimic transfected and MCVSyn-transfected cells 221 
compared with controls (Figure 5f), suggesting that MCV-miR-M1 negatively regulates 222 
neutrophil migration, in vitro, towards cells harbouring replicative MCPyV. To investigate if 223 
migration was due to attenuation of CXCL8 levels, neutrophil migration assays were repeated 224 
in the presence or absence of the CXCR2 antagonist, SB265610, which has been reported to 225 
block CXCL8-induced neutrophil migration in vitro and in vivo (Bradley et al., 2009). 226 
Treatment with SB265610 resulted in significant downregulation of neutrophil migration for 227 
both MCVSyn- and MCVSyn-hpko-transfected cells (Figure 5g). This reduction was more 228 
pronounced in MCVSyn-transfected cells, where MCV-miR-M1 induces CXCL8 229 
downregulation. These data suggest that MCV-miR-M1 mediates downregulation of 230 
neutrophil migration during virus replication at least in part via modulation of CXCL8 231 
secretion. 232 
MCV-miR-M1 targets SP100 and CXCL8 secretion in MCC cell lines resulting in 233 
attenuated neutrophil migration. 234 
Thus far data was obtained using the 293 cell line, which has been previously shown to 235 
facilitate the study of MCPyV virus-host cell interactions (Griffiths et al., 2013b, Kwun et al., 236 
2015, Wang et al., 2012) and act as a semi-permissive cell line for the MCVSyn system 237 
(Neumann et al., 2011). However, given the proposed function of MCV-miR-M1 in the 238 
establishment of persistent infection and our data suggesting that this might be achieved in 239 
part via the dysregulation of SP100 and CXCL8 secretion we were keen to demonstrate that 240 
MCV-miR-M1 functions in the same manner in Merkel cells, where quasi-latency is 241 
hypothesised to be a functional prerequisite for transformation. Merkel cells have been 242 
cultured in vitro alongside keratinocytes (Fradette et al., 2003), however, no Merkel cell-243 
specific tissue culture system is currently available. Therefore, to study MCV-miR-M1 in a 244 
Merkel cell background we utilised the MCPyV-negative MCC cell line, MCC13 and the 245 
MCPyV-positive cell line, MKL-1, which has been reported to be a representative model for 246 
MCC (Daily et al., 2015). MCC13 cells were transfected with MCV-miR-M1-5p, MCV-miR-247 
M1-3p and scramble mimic control and an analysis of SP100 and CXCL8 transcript and 248 
protein expression carried out, as described above. We detected significant changes in both 249 
SP100 and CXCL8 mRNA (Figure 6a) and protein levels (Figures 6b and 6c) that were 250 
consistent with data gathered using 293 cells. Moreover, neutrophil migration was also 251 
significantly reduced in both MCC cell lines expressing MCV-miR-M1 mimics (Figure 6d). 252 
These data confirm that MCV-miR-M1 modulates the expression of SP100 and CXCL8 in 253 
two MCC cell lines, resulting in reduced migration of neutrophils towards Merkel cells 254 
harbouring synthetic MCPyV genomes. 255 
Discussion 256 
Despite mounting evidence describing virus-encoded miRNAs as key regulators of host cell 257 
transcripts (Kincaid and Sullivan, 2012) for many virus miRNAs there is a lack of global 258 
target identification. Currently, there are no published data describing validated cellular 259 
targets of MCV-miR-M1. Using an unbiased RNA-seq-based approach we have identified 260 
numerous MCV-miR-M1-modulated cellular transcripts, including SP100, which is a 261 
constituent of Promyelocytic leukaemia protein-nuclear bodies (PML-NB), a nuclear protein 262 
complex involved in the regulation of transcription, apoptosis, cell cycle, response to stress 263 
and hormone signalling and development. While our RNA-seq data identified various cellular 264 
targets, many of which are involved in immune related processes, it is important to 265 
acknowledge that given the HEK293-cell background it is possible that some relevant targets 266 
were missed.  267 
SP100 is an intriguing MCV-miR-M1 target, which has been implicated in the innate immune 268 
response against dsDNA viruses, including MCPyV (Gunther et al., 2014, Jiang et al., 2011, 269 
Neumann et al., 2016, Tavalai and Stamminger, 2009, Wagenknecht et al., 2015) and has 270 
been shown to be downregulated during MCPyV replication, although no mechanism for this 271 
was reported (Neumann et al., 2016). Our data suggest that MCV-miR-M1 mediates (at least 272 
in part) the observed downregulation of SP100 in cells harbouring synthetic MCPyV. The 273 
argument for MCV-miR-M1 mediated downregulation, rather than modulation by one of the 274 
MCPyV proteins is strengthened by the fact that SP100 levels are not decreased in cells 275 
transfected with MCVSyn-hpko, which lacks MCV-miR-M1 expression but exhibits 276 
significantly increased expression of LT, sT and VP1 (Figures 3c and 4e and (Theiss et al., 277 
2015).  278 
A caveat of the MCV-hpko mutant in terms of its use as a negative control is that loss of 279 
MCV-miR-M1 expression results in increased levels of LT that may contribute to some of the 280 
observed effects. The use of MCV-miR-M1 mimics alongside MCVSyn has enabled us to 281 
corroborate putative MCV-miR-M1-specific effects observed using the synthetic virus in the 282 
absence of other MCPyV transcripts and proteins. While we consistently observed similar 283 
results between MCV-miR-M1 mimics and MCVSyn, we cannot rule out that elevated LT 284 
expression in MCVSyn-hpko cells may be contributing to some of our observations, in 285 
particular changes in CXCL8 secretion, where LT has been shown to increase CXCL8 286 
expression (Richards et al., 2015). However, mimic data suggest that MCV-miR-M1 can 287 
significantly impair CXCL8 expression in the absence of LT (Figure 5a). 288 
Our understanding of how PML-NBs and SP100 contribute to the antiviral response has 289 
improved in recent years (Nisole et al., 2013), however, mechanistically there is much still to 290 
unpick. Here we have shown that direct targeting of SP100 by MCV-miR-M1 modulates 291 
CXCL8 secretion. It has been reported that PML functions to regulate the expression of 292 
proinflammatory cytokines, including IL-6 and CXCL8 (Lunardi et al., 2011), however, it is 293 
not known if SP100 is also able to function in this manner. One explanation may be that 294 
SP100 is able to transcriptionally regulate CXCL8 either directly or in trans, a notion 295 
supported by previous work demonstrating that SP100 functions to activate ETS-family 296 
transcription factors (Wasylyk et al., 2002). However, as MCV-miR-M1-5p induces changes 297 
in secreted CXCL8, but does not alter CXCL8 transcript levels (Table S1 and Figure 6a), it 298 
seems more likely that MCV-miR-M1-5p-dysregulation of SP100 (or other unidentified 299 
cellular transcripts) impact on CXCL8 via a post-translational mechanism. Indeed, our 300 
observation that ectopic expression of pCDNA-SP100 only partially rescues the MCV-miR-301 
M1-5p mediated reduction of CXCL8 secretion strongly suggests that other MCV-miR-M1 302 
dysregulated factors are influencing CXCL8 secretion and presumably, in turn, neutrophil 303 
migration. Trans-well assays support this hypothesis, as both 5p and 3p MCV-miR-M1 304 
mimics diminished neutrophil chemotaxis to a similar level, despite MCV-miR-M1-3p 305 
having no effect on SP100 mRNA or protein levels. We are currently investigating if other 306 
indirect MCV-miR-M1 targets impair neutrophil migration during MCPyV replication. 307 
The functional significance of MCV-miR-M1-mediated attenuation of neutrophil chemotaxis 308 
for MCPyV remains to be established. One possibility that has been reported in -309 
herpesviruses (Zhu et al., 2013) and previously discussed for MCPyV (Theiss et al., 2015) is 310 
that by reducing the immunological footprint of MCPyV during replication the virus is more 311 
likely to establish a quasi-latent infection. Such a mechanism might explain how MCPyV is 312 
able to infect Merkel cells for a duration of time that permit rare MCPyV-genome integration 313 
events and subsequent transformation and development of MCC, although the absence of a 314 
non-transformed Merkel cell culture system makes this theory difficult to test. Recently, 315 
dermal fibroblasts were identified as the likely primary host cell type naturally and 316 
productively infected by MCPyV (Liu et al., 2016b). We are currently investigating MCV-317 
miR-M1-mediated attenuation of neutrophil chemotaxis in these cells and it will be of interest 318 
to determine how this impacts on commensal MCPyV infection in skin. In summary, we have 319 
employed an unbiased, RNA-seq based approach to identify cellular MCV-miR-M1 targets 320 
and shown that the innate immune response protein, SP100 is a direct target of MCV-miR-321 
M1-5p. Furthermore, we have demonstrated that there is a MCV-miR-M1-dependent 322 
decrease in neutrophil migration that may be contributing to the host cell immune evasion 323 
strategy of MCPyV following infection of Merkel cells.   324 
Materials & Methods 325 
Tissue culture 326 
Cells were purchased from ECACC and certified mycoplasma-free. 293 and Flp-In™ T-327 
REx™ 293-MCVmiR were maintained in DMEM media supplemented with 10% FBS, 100 328 
U/ml of penicillin and 100 µg/ml of streptomycin. MCC13 and MKL1 cells were maintained 329 
in RPMI 1640 media supplemented with 10% FBS, 100 U/ml of penicillin and 100 µg/ml of 330 
streptomycin. All cells were cultured at 37˚C and 5% CO2 and transfected using 331 
Lipofectamine 3000 as described (Boyne et al., 2010). 332 
RNA sequencing (RNA-Seq) 333 
293 cells were transfected with either MCV-miR-M1-5p, MCV-miR-M1-3p or control mimic 334 
(Thermo Fisher Scientific) prior to RNA extraction and confirmation of MCV miRNA 5p and 335 
3p expression via stem loop qRT-PCR. Total RNA libraries were prepared using TruSeq 336 
Stranded Total RNA Sample Prep Kit (Illumina, USA) and the TruSeq cDNA libraries were 337 
analysed via Illumina HiSeq2500 paired end 100bp. Differential gene expression and gene 338 
annotation analysis were carried out using edgeR software and DAVID annotation tool, 339 
respectively. RNA-seq data have been deposited in the ArrayExpress database at EMBL-EBI 340 
(www.ebi.ac.uk/arrayexpress) under accession number E-MTAB-6526. 341 
qRT-PCR 342 
Total RNA was extracted from cells and 500ng used to generate cDNA prior to qRT-PCR 343 
analysis using SsoAdvanced SYBR master mix (Bio-Rad, UK) on the CFX96 system (Bio-344 
Rad, UK).  345 
Stem loop qRT-PCR was carried out to detect MCV miRNA (Czimmerer et al., 2013). 346 
Briefly, stem loop cDNA was generated using a stem loop primer containing a MCV miRNA 347 
specific hexamer sequence. A forward primer complementary to MCV miRNA and a 348 
universal reverse primer were used to detect miRNA expression via qRT-PCR. qRT-PCR 349 
analysis of MCPyV genome copy number was performed as previously described (Theiss et 350 
al., 2015). A list of oligonucleotides used during this study can be found in Table S2. 351 
Protein analysis 352 
Human CXCL8 ELISA (eBioscience) was carried out as previously described (Bridgewood 353 
et al., 2017). SDS-PAGE and western blot analysis were performed as described (Schumann 354 
et al., 2016). Anti-SP100 and anti-LT (CM2B4) (Santa Cruz) were used at a dilution of 355 
1:1000, GAPDH (Abcam) was used at a dilution of 1:10000.  356 
Dual luciferase assay 357 
psiCHECK-2 expression construct was generated by inserting the respective 3’UTR response 358 
element downstream of Renilla luciferase (hRluc) gene. 293 cells were co-transfected with 359 
psiCHECK-2/3’UTR of interest and MCV miRNA mimics, control mimic or MCVSyn 360 
genomes, prior to Dual luciferase assay (DLA). 361 
Neutrophil isolation and migration assay 362 
Neutrophils were isolated from peripheral blood as previously described (Lau and Hunstad, 363 
2013). In vitro neutrophil migration was measured using transwell chambers. Briefly, 364 
neutrophils were seeded into the top chamber and cell supernatants were placed in the lower 365 
chamber. Plates were incubated at 37ºC and 5% CO2 for two hours prior to mixing the lower 366 
chamber contents with equal volume of CellTiter-Glo® 2.0 (Promega) and recording 367 
luminescence using a TECAN infinite M200 plate reader. 368 
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Figure 1: Comparative analysis of MCV-miR-M1 expression systems. 381 
Total RNA was extracted from doxycycline-induced MCV-miR-M1-293 cells and 293 cells 382 
transiently transfected with either pCDNA3.1-MCV-miR-M1 or MCV-miR-M1 mimics and 383 
cDNA generated prior to analysis of MCV-miR-M1-5p and MCV-miR-M1-3p expression via 384 
stem-loop qPCR, n=3 (a). 293 cells were co-transfected with either psiCHECK2 harbouring 385 
the cognate MCV-miR-M1 recognition sequence or a mutated control sequence alongside 386 
pCDNA3.1-MCV-miR-M1 or MCV-miR-M1 mimics and DLA performed to determine 387 
relative miRNA activity, n=3 (b). 388 
Figure 2: MCV-miR-M1 preferentially dysregulates cellular immune-response 389 
transcripts. 390 
RNA-seq was performed on total RNA extracted from 293 cells that had either been 391 
transfected in biological triplicate with scramble miRNA mimic, MCV-miR-M1-5p mimic or 392 
MCV-miR-M1-3p mimic. Analysis of differential expression of cellular transcripts by edgeR 393 
and subsequent gene ontology analysis using DAVID (a) identified a set of cellular 394 
transcripts that were significantly dysregulated by MCV-miR-M1 and involved in immune 395 
response (b).  396 
Figure 3: MCV-miR-M1 targets immune-response targets during MCPyV replication. 397 
293 cells were transiently transfected with MCV-miR-M1-5p, MCV-miR-M1-3p or scramble 398 
mimic control and expression of target transcript determined via qRT-PCR, n=3 (a). 293 cells 399 
were transfected with MCVSyn or MCVSyn-hpko genomes and total RNA and protein 400 
extracted 24h, 48h and 72h post-transfection for analysis of MCV-miR-M1-5p and MCV-401 
miR-M1-3p expression via stem-loop qRT-PCR (b) and LT expression by immunoblot (c), 402 
n=3. 293 cells were transfected with either MCVSyn of MCVSyn-hpko genomes and 403 
cultured for 72h prior to total RNA extraction and analysis of MCV-miR-M1 target 404 
expression by qRT-PCR, n=3 (d).  405 
Figure 4: MCV-miR-M1 directly targets the viral innate immune response protein, 406 
SP100. 407 
Full-length 3’UTRs of each validated target were analysed using RNA-hybrid to identify 408 
putative seed-sequence binding sites for MCV-miR-M1 (a). The full length 3’UTR regions of 409 
CXCL8, RAET1G, SELPLG and SP100 were PCR-amplified and cloned downstream of 410 
Renilla luciferase DLA assays performed via co-transfection of 293 cells with each 411 
recombinant 3’-UTR construct and either scramble control, MCV-miR-M1-5p or MCV-miR-412 
M1-3p mimic, n=3 (b). DLA assays carried out via co-transfection of 293 cells with scramble 413 
control mimic, MCV-miR-M1-5p mimic, MCV-miR-M1-3p mimic, MCVSyn or MCVSyn-414 
hpko and either wild-type SP100 3’-UTR (c) or the mutant SP100 3’-UTR (d), n=3. 293 cells 415 
were transfected with either scramble mimic control, MCV-miR-M1-5p mimic, MCV-miR-416 
M1-3p mimic, MCVSyn or MCVSyn-hpko and cultured for 48h prior to isolation of total 417 
protein and analysis by immunoblot, n=3 (e).  418 
Figure 5: MCV-miR-M1 mediates a reduction in the secretion of CXCL8 that impairs 419 
neutrophil chemotaxis. 420 
Conditioned media was collected 24h post-transfection from TNF-α stimulated 293 cells 421 
transfected with either scramble mimic, MCV-miR-M1-5p mimic or MCV-miR-M1-3p 422 
mimic and relative CXCL8 levels determined via ELISA, n=3 (a). 293 cells were transfected 423 
with either MCVSyn or MCVSyn-hpko genomes (in the absence of TNF-) and conditioned 424 
media collected 72h post-transfection for analysis of CXCL8 secretion via ELISA, n=3 (b). 425 
293 cells were treated as described in (a) and (b) above with the addition of either pCDNA3.1 426 
(-) or pcDNA-SP100 (SP100) to the transfection mix. Total protein was isolated and SP100 427 
expression assessed via immunoblot (c), alongside this, conditioned media was collected for 428 
analysis of CXCL8 secretion via ELISA (d and e), n=3. 293 cells were stimulated with TNF-429 
α prior to transfection with either scramble mimic, MCV-miR-M1-5p mimic or MCV-miR-430 
M1-3p and cultured for 24h before isolating conditioned growth media, alongside these 293 431 
cells were also transfected with MCVSyn or MCVSyn-hpko and cultured for 72h prior to 432 
collection of conditioned growth media. Both sets of conditioned media obtained above were 433 
then used in neutrophil chemotaxis trans-well migration assay, n=3 (f). 293 cells were 434 
transfected with MCVSyn or MCVSyn-hpko in the presence or absence of SB265610 and 435 
cultured for 72h prior to collection of conditioned growth media and neutrophil chemotaxis 436 
trans-well migration assay, n=3 (g). 437 
Figure 6: MCV-miR-M1 mediated attenuation of CXCL8 secretion and neutrophil 438 
chemotaxis also occurs in Merkel cells. 439 
MCC13 or MKL-1 cells were transfected with either scramble mimic, MCV-miR-M1-5p 440 
mimic or MCV-miR-M1-3p mimic and cultured for 24h before isolating total RNA for 441 
analysis of CXCL8 and SP100 transcripts levels via qRT-PCR, n=3 (a), total protein isolation 442 
for the analysis of SP100 expression by immunoblot, n=3 (b). MCC13 or MKL-1 cells were 443 
stimulated with TNF-α prior to transfection with either scramble mimic, MCV-miR-M1-5p 444 
mimic or MCV-miR-M1-3p and cultured for 24h before the collection of conditioned growth 445 
media and analysis of secreted CXCL8 levels via ELISA, n=3 (c) and neutrophil chemotaxis 446 
by trans-well migration assay, n=3 (d).  447 
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